BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24650159)

  • 1. Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer.
    Nishihara K; Nakiri M; Chikui K; Suekane S; Matsuoka K; Hattori C; Ogo E; Abe T; Matsumoto Y; Ishitake T
    Int J Urol; 2014 Jul; 21(7):658-63. PubMed ID: 24650159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
    Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
    Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
    Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator.
    Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM
    Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
    Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
    Stock RG; Stone NN; Cesaretti JA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.
    Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Morizawa Y; Hori S; Owari T; Fujii T; Yamaki K; Hasegawa M; Fujimoto K
    Jpn J Clin Oncol; 2020 Jan; 50(1):58-65. PubMed ID: 31665354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy.
    Kanzaki H; Kataoka M; Nishikawa A; Uwatsu K; Nagasaki K; Nishijima N; Hashine K
    Jpn J Clin Oncol; 2015 Jul; 45(7):688-94. PubMed ID: 25888709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.
    Mazeron R; Bajard A; Montbarbon X; Gassa F; Malet C; Rocher F; Clippe S; Bringeon G; Desmettre O; Pommier P
    Radiat Oncol; 2012 Mar; 7():46. PubMed ID: 22449081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer.
    Kanai K; Nakashima J; Sugawara A; Shigematsu N; Nagata H; Kikuchi E; Miyajima A; Nakagawa K; Kubo A; Oya M
    Int J Clin Oncol; 2009 Dec; 14(6):502-6. PubMed ID: 19967485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer.
    Kubo K; Wadasaki K; Kimura T; Murakami Y; Kajiwara M; Teishima J; Matsubara A; Nagata Y
    J Radiat Res; 2018 Sep; 59(5):649-655. PubMed ID: 30085076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer].
    Morita M; Lederer JL; Fukagai T; Shimada M; Yoshida H
    Nihon Hinyokika Gakkai Zasshi; 2004 Mar; 95(3):609-15. PubMed ID: 15103924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
    Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
    J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
    Hinnen KA; Monninkhof EM; Battermann JJ; van Roermund JG; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):883-8. PubMed ID: 21300477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce.
    Das P; Chen MH; Valentine K; Lopes L; Cormack RA; Renshaw AA; Tempany CM; Kumar S; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):698-702. PubMed ID: 12377320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients.
    Leduc N; Atallah V; Creoff M; Rabia N; Taouil T; Escarmant P; Vinh-Hung V
    Brachytherapy; 2015; 14(6):826-33. PubMed ID: 26489920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.